Settings, Trust, and Time in Range: Optimizing Omnipod® 5 with Dr. Sufyan Hussain

Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data.

Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems.

The conversation also covers real patient stories, including individuals with significant fear of hypoglycemia and lower health and tech literacy, who saw meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy.

Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care.

00:00 - Why real-world evidence (RWE) matters

05:12 - Key real-world insights: Equity, simplicity, and outcomes

08:12 - Optimizing Omnipod 5 settings for improved clinical results

15:24 - Expanding access: Patient success stories and the power of simplicity

1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.

How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).

Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.

If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.